<DOC>
	<DOCNO>NCT01324947</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety pomalidomide monotherapy subject refractory relapse refractory multiple myeloma enrol study CC-4047-MM-003 ( NCT01311687 ) discontinue treatment high-dose dexamethasone due disease progression .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Pomalidomide Monotherapy Subjects With Refractory Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Subjects refractory relapse refractory multiple myeloma enrol Study CC4047MM003 discontinue study therapy dexamethasone alone ( Treatment Arm B ) least start second cycle dexamethasone treatment due development document disease progression accord International Myeloma Working Group ( IMWG ) criterion decide Independent Review Adjudication Committee ( IRAC ) . 2 . Must ≥ 18 year time signing informed consent form . 3 . The subject must understand voluntarily sign informed consent document prior study related assessments/procedures conduct . The exception skeletal survey perform within 90 day prior start Cycle 1 , new survey require . 4 . Must able adhere study visit schedule protocol requirement . 5 . Subjects must document diagnosis multiple myeloma measurable disease ( serum Mprotein ≥ 0.5g/dL urine Mprotein ≥ 200 mg/24 hour ) . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 . 7 . Females childbearing potential ( FCBP† ) must agree utilize two reliable form contraception simultaneously practice true abstinence [ line prefer usual lifestyle subject . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , post ovulation method ) withdrawal acceptable method contraception ] heterosexual contact least 28 day start study drug , participate study ( include dose interruption ) , least 28 day study treatment discontinuation must agree regular pregnancy test timeframe . 8 . Females must agree abstain breastfeed study participation 28 day study discontinuation . 9 . Males must agree either use latex condom sexual contact FCBP practice true abstinence [ line prefer usual lifestyle subject . Periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception ] participate study 28 day follow discontinuation study , even undergone successful vasectomy . . 10 . Males must also agree refrain donate semen sperm pomalidomide 28 day discontinuation study treatment . 11 . All subject must agree refrain donate blood study drug 28 day discontinuation study treatment . 12 . All subject must agree share study medication Exclusion Criteria The presence follow exclude subject enrollment : 1 . Subjects multiple myeloma treat part Study CC4047MM003 ( Arm B ) . 2 . Subjects receive antimyeloma anticancer therapy within last 14 day washout period initiation study treatment . 3 . Subjects discontinue CC4047MM003 study ≥120 day . 4 . Subjects initiate another antimyeloma therapy time disease progression study CC4047MM003 time treatment initiation companion study . 5 . Any following laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,000/µL . Platelet count &lt; 75,000/µL subject &lt; 50 % bone marrow nucleate cell plasma cell ; platelet count &lt; 30,000/µL subject ≥ 50 % bone marrow nucleate cell plasma cell Creatinine Clearance &lt; 45 mL/min accord CockcroftGault formula ( If creatinine clearance calculate 24hour urine sample ≥45 ml/min , patient qualify trial ) Corrected serum calcium &gt; 14 mg/dL ( &gt; 3.5 mmol/L ) ; Hemoglobin &lt; 8 g/dL ( &lt; 4.9 mmol/L ; prior RBC transfusion recombinant human erythropoietin use permit ) Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) Serum total bilirubin &gt; 2.0 mg/dL ( 34.2 μmol/L ) ; &gt; 3.0 x ULN subject hereditary benign hyperbilirubinaemia 6 . Prior history malignancy , Multiple Myeloma ( MM ) , unless subject free disease ≥ 5 year . Exceptions include follow : Basal Squamous cell carcinoma skin Carcinoma situ cervix breast Incidental histologic find prostate cancer ( TNM stage T1a T1b ) 7 . Hypersensitivity thalidomide lenalidomide . ( This include ≥ Grade 3 rash prior thalidomide lenalidomide therapy ) . 8 . Peripheral neuropathy ≥ Grade 2 . 9 . Subjects receive allogeneic bone marrow allogeneic peripheral blood stem cell transplant le 12 month prior initiation study treatment discontinue immunosuppressive treatment least 4 week prior initiation study treatment currently dependent treatment . 10 . Subjects plan eligible stem cell transplant . 11 . Subjects one following : Congestive heart failure ( NY Heart Association Class III IV ) Myocardial infarction within 12 month prior start study treatment Unstable poorly control angina pectoris , include Prinzmetal variant angina pectoris 12 . Subjects receive follow within last 14 day initiation study treatment : Plasmapheresis Major surgery ( kyphoplasty consider major surgery ) Radiation therapy 13 . Use investigational agent within 28 day 5 half life ( whichever longer ) treatment . 14 . Subjects chronic condition rheumatoid arthritis , multiple sclerosis lupus , likely need additional steroid immunosuppressive treatment addition study treatment . 15 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 16 . Incidence gastrointestinal disease may significantly alter absorption pomalidomide . 17 . Subjects unable unwilling undergo antithrombotic prophylactic treatment . 18 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 19 . Pregnant breastfeeding female . 20 . Known human immunodeficiency virus ( HIV ) positivity active infectious hepatitis A , B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Relapsed Refractory Multiple Myeloma</keyword>
	<keyword>Refractory Myeloma</keyword>
	<keyword>Resistant Multiple Myeloma</keyword>
	<keyword>Treatment-resistant Multiple Myeloma</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>Lenalidomide-resistant</keyword>
	<keyword>Bortezomib-resistant</keyword>
	<keyword>Companion</keyword>
</DOC>